Investing is often filled with tough choices and opportunity costs. This game segment from The Motley Fool's Where The Money Is poses a hypothetical question:

Would you rather short Johnson & Johnson (NYSE:JNJ) or buy Dendreon (NASDAQOTH:DNDNQ)?

Healthcare analysts David Williamson and Michael Douglass continue their game of "would you rather" by discussing a blue chip stalwart and a biotech struggling with lackluster sales. Watch and find out which strategy David chooses and his arguments for it. 

David Williamson owns shares of Johnson & Johnson. Michael Douglass has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.